Skip to content
WeighLab
Menu
Ranked #410 · Grade C

MDLive review

MDLIVE is a large.

Visit MDLive Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. See our disclosure.
Semaglutide
Not disclosed
Tirzepatide
Not disclosed
Coverage
Coverage not published
Brand-name
Yes

Pricing verified August 2026

The Index scorecard

MDLive scored on our six Cost-Efficiency Index factors. See the methodology.

Normalized Cost/Month45/100
Price Transparency54/100
Nationwide Access24/100
Formulation Options53/100
Clinical Oversight85/100
Contract Flexibility55/100

Where the value is

  • Backed by a major, established telehealth/insurance parent (Evernorth/Cigna)
  • Access to FDA-approved branded anti-obesity medications, not unregulated compounds
  • Broad general primary-care telehealth infrastructure

The tradeoffs

  • No dedicated GLP-1 or weight-loss program -- medications are folded into general primary care visits only
  • No medication-specific pricing published anywhere
  • Explicitly unavailable in Florida, Louisiana, Mississippi, and New Jersey
  • Availability is 'at the doctor's discretion,' with no guarantee of prescribing

The bottom line

Best for: Cost-first shoppers who want not a fit for GLP-1 price shopping -- best suited to patients who already have MDLIVE access for general primary care. MDLIVE is a large.

Ranked #410 of 539 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.

Compare with other providers

All 538 other providers we've modeled, in Cost-Efficiency Index order. See the ranked alternatives to MDLive.

The 24 programs nearest this one

Pricing, states and verification reflect MDLive's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on MDLive's site. Not medical advice; see our disclosure.

← Back to the value leaderboard